Table 1.
Associations* between HLA–DRB1 Two-Field Alleles and Sarcoidosis Risk
| Allele Frequency |
Full Sample |
Study-Specific Odds Ratios (95% CI) |
||||||
|---|---|---|---|---|---|---|---|---|
| Allele | Controls (n = 1,467) | Cases (n = 1,277) | OR* (95% CI)* | P Value* | ACCESS† | SAGA† | HFH† | Phet |
| 01:01 | 0.025 | 0.014 | 0.56 (0.37–0.85) | 0.006 | 0.60 (0.28–1.29) | 0.57 (0.24–1.36) | 0.74 (0.35–1.56) | 0.894 |
| 03:01 | 0.069 | 0.042 | 0.56 (0.44–0.73) | 1.0 × 10−5 | 0.74 (0.47–1.18) | 0.69 (0.38–1.26) | 0.57 (0.37–0.89) | 0.730 |
| 03:02 | 0.074 | 0.091 | 1.26 (1.03–1.56) | 0.027 | 1.28 (0.86–1.93) | 2.07 (1.20–3.59) | 1.07 (0.77–1.50) | 0.136 |
| 07:01 | 0.082 | 0.063 | 0.74 (0.59–0.93) | 0.009 | 0.93 (0.62–1.41) | 0.67 (0.40–1.11) | 0.81 (0.56–1.17) | 0.620 |
| 09:01 | 0.026 | 0.016 | 0.64 (0.43–0.95) | 0.027 | 0.61 (0.27–1.37) | 1.69 (0.62–4.59) | 0.43 (0.21–0.90) | 0.118 |
| 11:01 | 0.113 | 0.167 | 1.69 (1.42–2.01) | 3.0 × 10−9 | 1.80 (1.28–2.53) | 1.09 (0.75–1.57) | 1.55 (1.16–2.07) | 0.088 |
| 12:01 | 0.043 | 0.077 | 2.11 (1.65–2.69) | 3.2 × 10−9 | 2.06 (1.29–3.28) | 2.75 (1.49–5.06) | 1.35 (0.91–2.01) | 0.139 |
| 13:04 | 0.020 | 0.012 | 0.55 (0.33–0.92) | 0.023 | 0.50 (0.18–1.44) | 0.82 (0.27–2.45) | 0.45 (0.16–1.25) | 0.632 |
| 15:03 | 0.123 | 0.101 | 0.79 (0.66–0.95) | 0.011 | 0.68 (0.46–1.00) | 0.69 (0.46–1.02) | 0.89 (0.66–1.20) | 0.505 |
Definition of abbreviations: ACCESS, A Case-Control Etiologic Study of Sarcoidosis; CI, confidence interval; HFH, Henry Ford Hospital; OR, odds ratio; Phet, P value for heterogeneity; SAGA, Sarcoidosis Genetic Analysis.
Associations with P < 0.05. Models were estimated using generalized estimating equations, and the allele odds ratios are estimated assuming a dominant model adjusted for sex and genome-wide percent African ancestry. P values were calculated using a Wald test.
The study-specific sample sizes are as follows: ACCESS (n = 1,034; 224 patients with sarcoidosis and 810 control subjects), SAGA (n = 741; 566 patients with sarcoidosis and 175 control subjects), and HFH (n = 969; 487 patients with sarcoidosis and 482 control subjects).